Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 3 reviews

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 4 · 66.7%Moderate 0 · 0%High 0 · 0%

Oral + inhaled dual therapy vs oral monotherapy

Serious adverse events. Outcome assessed on day 42 · bronchiectasis

It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).

1 finding from 1 review

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).

1 finding from 1 review

Hyperimmune immunoglobulin from human plasma vs saline placebo

Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19

Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).

1 finding from 1 review